Eric Marshall, MD
Family Medicine · Washington, DCNPI 1841228947
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,454 and has fallen 91.8% since, to $120 in 2025. Among family medicine clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$365
- Novo Nordisk$357
- Pfizer$313
- Amgen$189
- Merck$141
- AbbVie$125
- plus $666 from 16 others
What the payments were for
- Food & beverage$2,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $365 |
| Novo Nordisk | 23 | $357 |
| Pfizer | 16 | $313 |
| Amgen | 10 | $189 |
| Merck | 12 | $141 |
| AbbVie(2 entities) | 6 | $125 |
| Gilead | 5 | $97 |
| Lilly USA, LLC | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Astellas Pharma US Inc | 4 | $73 |
| Novartis | 3 | $57 |
| Hikma Pharmaceuticals USA | 4 | $55 |
| Boehringer Ingelheim | 2 | $50 |
| Johnson & Johnson | 2 | $34 |
| Exact Sciences | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Heartflow, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $10 |
How this compares
$2,157 in reported general payments places this provider in the 90th percentile of 166 family medicine providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 93 | $137,969 |
| RybelsusSemaglutide | 52 | $93,103 |
| TrulicityDulaglutide | 43 | $88,665 |
| EliquisApixaban | 84 | $83,804 |
| LinzessLinaclotide | 63 | $56,243 |
| OzempicSemaglutide | 31 | $53,793 |
| PercocetOxycodone Hcl/Acetaminophen | 12 | $44,879 |
| XareltoRivaroxaban | 19 | $29,514 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $28,347 |
| MounjaroTirzepatide | 23 | $25,190 |
| Spiriva RespimatTiotropium Bromide | 15 | $20,952 |
| JanuviaSitagliptin Phosphate | 17 | $20,051 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $19,580 |
| FarxigaDapagliflozin Propanediol | 11 | $19,478 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $15,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $50 | $158,921108 claims |
| Novo NordiskRybelsus, Ozempic | $357 | $146,89683 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $83 | $113,85566 claims |
| PfizerEliquis | $313 | $83,80484 claims |
| MerckJanumet Xr, Januvia, Janumet | $141 | $61,78757 claims |
| AbbVieLinzess | $125 | $56,24363 claims |
| Johnson & JohnsonXarelto | $34 | $29,51419 claims |
| AstraZenecaFarxiga | $365 | $19,47811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 166 family medicine providers in District of Columbia.
Other family medicine in Washington
- Mark JohnsonWashington$38K
- Charles GreenWashington$25K
- Barry ClarkWashington$17K
- Joel AngWashington$14K
- Kandie TateWashington$12K
- Ghulam AbbasWashington$9K
- Megha MendirattaWashington$6K
- Minerva CamposWashington$5K
- Kathleen UhlWashington$5K
- Mikel HofmannWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.